04th week of 2014 patent applcation highlights part 35 |
Patent application number | Title | Published |
20140023549 | AUSTENITIC STAINLESS STEEL - Provided is an austenitic stainless steel having excellent surface glossiness. | 2014-01-23 |
20140023550 | FERRITIC STAINLESS STEEL SHEET EXCELLENT IN HEAT RESISTANCE AND WORKABILITY AND METHOD OF PRODUCTION OF SAME - The present invention provides ferritic stainless steel sheet which is excellent in heat resistance at 950° C. and workability at ordinary temperature, that is, ferritic stainless steel sheet excellent in heat resistance and workability which is characterized by containing, by mass %, C: 0.02% or less, N: 0.02% or less, Si: over 0.1 to 1.0%, Mn: 0.5% or less, P: 0.020 to 0.10%, Cr: 13.0 to 20.0%, Nb: 0.5 to 1.0%, Cu: 1.0 to 3.0%, Mo: 1.5 to 3.5%, W: 2.0% or less, B: 0.0001 to 0.0010%, and Al: 0.01 to 1.0% and having a balance of Fe and unavoidable impurities, where Mo+W is made 2.0 to 3.5%. | 2014-01-23 |
20140023551 | PROCESS FOR SETTING THE THERMAL CONDUCTIVITY OF A STEEL, TOOL STEEL, IN PARTICULAR HOT-WORK STEEL, AND STEEL OBJECT - A tool steel, in particular a hot-work steel, has the following composition: 0.26 to 0.55% by weight C; less than 2% by weight Cr; 0 to 10% by weight Mo; 0 to 15% by weight W; wherein the W and Mo contents in total amount to 1.8 to 15% by weight; carbide-forming elements Ti, Zr, Hf, Nb, Ta forming a content of from 0 to 3% by weight individually or in total; 0 to 4% by weight V; 0 to 6% by weight Co; 0 to 1.6% by weight Si; 0 to 2% by weight Mn; 0 to 2.99% by weight Ni; 0 to 1% by weight S; remainder: iron and inevitable impurities. The hot-work steel has a significantly higher thermal conductivity than known tool steels. | 2014-01-23 |
20140023552 | NANOWIRE PREPARATION METHODS, COMPOSITIONS, AND ARTICLES - Methods of producing metal nanowires, compositions, and articles are disclosed. Such methods allow production of metal nanowires with reproducibly uniform diameter and length, even in the presence of catalyst concentration variation. Such metal nanowires are useful for electronics applications. | 2014-01-23 |
20140023553 | CORROSION INHIBITING SELF-EXPANDING FOAM - A corrosion prevention and control composition and method comprises combining primarily two-component polyurethane foam formed by reacting polyols with an isocyanate compound, and a 2 to 10 percent by weight of either an organic or inorganic gas-phase corrosion inhibitor. The closed cell foam provides a barrier protection for the underlying corrodible surface, while the inhibitor protects the metal from the absorbed moisture vapor, thereby preventing corrosion from occurring at the foam/metal interface. The resulting foam and inhibitor composition maintains better adhesion to the underlying corrodible structure in corrosive environments. | 2014-01-23 |
20140023554 | Plasma Powder Sterilization Apparatus and Methods - Systems and methods for plasma sterilization are described. The sterilization method includes placing a substance to be sterilized in a rotating chamber (e.g., drum) and exposing the substance to a radio frequency (RF) plasma. The mixing of the substance and plasma is further promoted by generating a magnetic field that produces a force on the substance in a direction opposite to the rotational direction of the chamber. In other aspects, the chamber may have a gas permeable wall. In addition, the substance may be exposed to acoustic shock waves produced by a modulating RF generator. | 2014-01-23 |
20140023555 | FORMULATIONS AND METHODS TO REDUCE HEXAVALENT CHROME CONTAMINATION - The present invention includes formulations and methods to reduce Cr(VI) contamination, in which the formulation comprises (1) a reactive reducing agent comprising at least one reducing chemical capable of reducing Cr(VI) to Cr(III); and (b) one or more solvents. Moreover, the present invention includes formulations to reduce Cr(VI) within the coating, and Cr(VI) reducing kits with at least one color reference tool for evaluating the process and/or completion of the Cr(VI) reduction. | 2014-01-23 |
20140023556 | Smart Home System And Operation Method Thereof - A smart home system having a controller which controls an ozone generator, gas supply outlets connected to gas supply outlets of the ozone generator via a pipe, and solenoid valves which control opening and closing of the gas supply outlets. The controller is connected with each of the solenoid valves and controls opening and closing of each of the solenoid valves. An operation method for the system discloses driving the ozone generator by the controller to generate ozone, controlling opening of the solenoid valves by the central processor when the central processor receives an external signal for opening the solenoid valves, reducing opening level of the solenoid valves when a gas flow sensor detects that the ozone flow rate passing through the gas inlet is greater than the flow rate threshold, and controlling closing of the solenoid valves by the central processor when the central processor receives a signal for closing the solenoid valves. | 2014-01-23 |
20140023557 | ELECTRONIC NOSE DEVICE - An electronic nose device is disclosed in an embodiment of the invention. The electronic nose device includes a fan module, a gas molecule sensor module, a control unit and an output unit. The fan module is used to pump air actively to the gas molecule sensor module. The gas molecule sensor module detects the air pumped into by the fan module. The gas molecule sensor module at least includes a gas molecule sensor which is covered with a compound. The compound is used to combine preset gas molecules. The control unit controls the fan module to suck air into the electronic nose device. Then the fan module transmits an air current to the gas molecule sensor module to generate a detected data. The output unit calculates the detected data to generate a calculation result and outputs an indicating signal to an operator or compatible host computer according to the calculation result. | 2014-01-23 |
20140023558 | SPACE DISINFECTION - A method for disinfecting a volume or surfaces bounding a volume comprising nebulising a solution comprising a sterilizing agent in a solvent having a lower boiling point than the sterilizing agent, for example ultrasonic nebulization of aqueous hydrogen peroxide, to form a nebulant. The nebulant is subjected to energy of a kind and for a duration sufficient to vaporize solvent in preference to sterilizing agent, eg heating element means, infra red, laser, microwave, RF or other radiation generating means; induction heating means; heat exchanger means; conduction means; convection means; or mechanical energy transfer means to increase the concentration of the agent in the nebulant particles. Vaporized solvent is removed from the gas stream at or above atmospheric pressure and, if necessary, the nebulant is cooled to below 70° C. The volume or surfaces are exposed to the nebulant for a time sufficient to sterilize said volume or surfaces. Also, apparatus for carrying out the method. | 2014-01-23 |
20140023559 | Cleaning Tool for Cleaning Particles Contained in a Slurry - A cleaning tool that includes an acoustic cavitation duct that cleans particles within a continuous flow of slurry. In one embodiment, the acoustic cavitation duct includes an elongated fluid passageway for carrying the flow of slurry. A number of ultrasonic transducers are spaced from one another along the length of the passageway and induce cavitation into the slurry as it travels through the duct. The cavitation promotes the cleaning of the slurry particles. In one example, the transducers operate at differing frequencies. | 2014-01-23 |
20140023560 | Anti-Soot Reformer - A novel reformer is provided. A gas fuel is guided from a fuel channel. Air and water are guided from a liquid/gas channel. They are mixed together in a mixing space. On mixing them, the temperature of the mixing space is between 150° C. and 300° C. Thus, the reactants are preheated and fully mixed; and a proper temperature is reached to avoid local over-heating and to prevent carbon deposited. | 2014-01-23 |
20140023561 | EXHAUST CLEANER FOR INTERNAL COMBUSTION ENGINE - The exhaust cleaner for internal combustion engine is equipped with NOx storage reduction catalyst ( | 2014-01-23 |
20140023562 | Base Oil Manufacturing Plant - We provide a process to manufacture a base stock, comprising hydrocracking, separating, and dewaxing, wherein the base stock has a ratio of Noack volatility to CCS VIS at −25° C. multiplied by 100 from 0.15 to 0.40. We also provide a base stock made by a process, and a base oil manufacturing plant that produces the base stock. | 2014-01-23 |
20140023563 | Paraxylene Production Process And Apparatus - The invention concerns a process for the production of paraxylene and an apparatus suitable for said process. The process separates the overhead from a xylenes re-run into a xylene-rich stream and a xylene-lean stream. The xylene-lean stream is isomerized under conditions such that the xylenes are in the liquid phase. | 2014-01-23 |
20140023564 | MICROFLUIDIC STORAGE DEVICE FOR PRE-STORING OF FLUID, METHOD FOR ITS PRODUCTION AND A USE THEREOF - A microfluidic storage device for pre-storing a fluid includes a first substrate, a second substrate, and a membrane. The first substrate has a recess formed in a first surface. The second substrate has a second surface formed to form fit with the first surface at least in subregions outside the recess. The membrane is arranged between the first and second substrates and is in contact with the first and second surfaces in regions outside the recess. In the region of the recess, the membrane is configured to line the recess so that a volume region inside the recess, between the membrane and the second substrate, can be filled with the fluid. The first substrate, the membrane, and the second substrate are configured to be joined together at least in subregions, outside the recess, in which the membrane is in contact with the first and second surfaces. | 2014-01-23 |
20140023565 | REAGENT STORAGE IN MICROFLUIDIC SYSTEMS AND RELATED ARTICLES AND METHODS - Fluidic devices and methods including those that provide storage and/or facilitate fluid handling of reagents are provided. Fluidic devices described herein may include channel segments positioned on two sides of an article, optionally connected by an intervening channel passing through the article. The channel segments may be used to store reagents in the device prior to first use by an end user. The stored reagents may include fluid plugs positioned in linear order so that during use, as fluids flow to a reaction site, they are delivered in a predetermined sequence. The specific geometries of the channel segments and the positions of the channel segments within the fluidic devices described herein may allow fluid reagents to be stored for extended periods of time without mixing, even during routine handling of the devices such as during shipping of the devices, and when the devices are subjected to physical shock or vibration. | 2014-01-23 |
20140023566 | FLUID HANDLING DEVICE AND FLUID HANDLING SYSTEM - The present invention relates to a microchannel chip capable of preventing fluid leakage caused by a lamination defect. Bottomed first regions, second regions, and third regions are formed by joining a film to a lower surface of the chip main body of a microchannel chip. The third regions are in communication with the second regions and are formed on carbon inks. The third regions are formed wider than the carbon inks are. The third regions are filled with an electroconductive adhesive. | 2014-01-23 |
20140023567 | FILTER VIAL - A filter vial for separating biological and chemical fluids has a cylindrical sidewall with an open top and a closed bottom. A protrusion extends upwards from the middle of the bottom to form an annular recess. A tubular plunger has an open bottom end to which is fastened an annular cup having an outer sidewall sized to fit into and seal against the vial's sidewall. An inner sidewall of the annular cup holds a filter over an opening in the bottom of the plunger and forms a shaped cavity leading to that filter. The annular cup on the plunger fits into the annular recess in the vial to force fluid from the vial through the filter and into the plunger. | 2014-01-23 |
20140023568 | BIO CARTRIDGES - A bio cartridge includes a reaction chamber disposed within a housing and containing a reagent, a specimen transfer channel providing a transfer path through which a specimen supplied to the housing is transferred into the reaction chamber, a mixing unit mixing the specimen with the reagent, and an air pressure unit providing air pressure to the specimen. | 2014-01-23 |
20140023569 | Suction Device for a Matrix Array of Pipette Tips - A suction device for a matrix array of pipette tips includes a tray configured to hold a liquid dispensed by the pipette tips. The tray includes an open-pore tray bottom. A suction tray cooperates with the open-pore tray bottom so as to form a vacuum chamber with the open-pore tray bottom forming a constituent of the vacuum chamber. A suction element is indirectly connected to the tray via the vacuum chamber so as to be configured to actively draw liquid over an entire surface into the vacuum chamber by suction via the tray bottom. | 2014-01-23 |
20140023570 | MODIFIED POLY (STYRENE-CO-MALEIC ANHYDRIDE) AND USES THEREOF - A polymeric compound is provided having the general formula (A) wherein R is an alkyl chain preferably having from 1 to 6 carbon atoms in the chain which may be either saturated or unsaturated and may have substituents attached to the chain, and R′ and R″, which may be the same or different from each other and preferably have from 1 to 4 carbon atoms in a chain, are selected from alkyl groups, substituted or unsubstituted, or R′ and R″ are linked to form a saturated or unsaturated cyclic moiety incorporating the adjacent nitrogen atom, with or without additional heteroatoms in the ring. The polymeric compound is preferably in a particulate form and most particularly in the form of nanoparticles. A method of producing the polymers is disclosed. A method of adsorbing, separating and stripping the polymers is also disclosed. | 2014-01-23 |
20140023571 | METHOD OF RECOVERING RARE EARTHS FROM A SOLID MIXTURE CONTAINING A HALOPHOSPHATE AND A RARE EARTH COMPOUND AND SOLID MIXTURES SUITABLE FOR THIS METHOD - An acid treatment, in a liquid medium, of a solid containing a halophosphate and a rare earth compound is described. Further described, is the addition of a base to the medium obtained previously and separation of a solid phase from a liquid phase; mixing and calcination of the solid obtained previously with an alkaline solid compound; redispersing the calcined product in water, separation of the solid product from the suspension obtained in the preceding step; dispersing this solid in water and acidification of the dispersion and separation of the solid from this dispersion. | 2014-01-23 |
20140023572 | METHOD OF ORE PROCESSING - A method of selectively leaching a metal such as nickel from an ore or ore processing intermediate comprising the metal and cobalt. The ore or ore processing intermediate is contacted with an acidic leach solution comprising an amount of an oxidising agent sufficient to oxidise a major portion of the cobalt to thereby cause it to be stabilised in the solid phase while a major portion of the metal is dissolved for subsequent recovery. | 2014-01-23 |
20140023573 | PROCESS FOR CONTROLLING CARBONYL SULFIDE PRODUCED DURING CHLORINATION OF ORES - The present invention provides for a process for handling carbonyl sulfide waste and waste metal halides produced in industrial processes and, more particularly chlorination processes. The process includes the steps of hydrolyzing the carbonyl sulfide to produce a waste stream containing hydrogen sulfide and sulfidizing the resulting hydrogen sulfide containing stream with a solution of the waste metal halides. The resulting metal sulfide and metal halide-containing stream can be neutralized before disposal of the produced waste solids. | 2014-01-23 |
20140023574 | Recovery of high purity lead oxide from lead acid battery paste - The invention relates to the low temperature recovery of lead oxide (PbO) from lead acid battery paste through the preparation of lead carboxylate from the battery paste and the conversion of the lead carboxylate to PbO. | 2014-01-23 |
20140023575 | Particulate Matter and Methods of Obtaining Same from a Kraft Waste Reclamation - The present invention relates in general to a method of scrubbing a waste gas, the method comprising: mixing HBr with washed dregs from a pulp mill green liquor clarifier to produce an activated carbon capable of oxidizing mercury; injecting the activated carbon slurry with HBr into a waste gas containing mercury at a temperature of from about 600° F. to about 900° F., thereby drying the activated carbon and oxidizing the mercury; and collecting the dried activated carbon and oxidized mercury on a filter. | 2014-01-23 |
20140023576 | SYSTEMS AND METHODS FOR REDUCING SECONDARY EMISSIONS FROM CATALYST COMPONENTS - System and methods for reducing secondary emissions in an exhaust stream from an internal combustion engine are disclosed. The systems and methods include a filtration device positioned downstream from an SCR catalyst of an aftertreatment system disposed in the exhaust system. The filtration device can also be used for particulate filter diagnostics and for treatment of ammonia slip. | 2014-01-23 |
20140023577 | METHOD FOR TREATING A CARBON DIOXIDE-CONTAINING WASTE GAS FROM AN ELECTROFUSION PROCESS - A method for treating a carbon dioxide-containing waste gas from an eletrofusion process, in which a hydrocarbon-containing gas is fed to a waste gas and the carbon dioxide in the waste gas is converted at least partially into carbon monoxide and hydrogen in a reaction and the carbon monoxide-hydrogen mixture is stored for an additional combustion process. | 2014-01-23 |
20140023578 | REACTOR SYSTEM AND METHOD OF POLYCRYSTALLINE SILICON PRODUCTION THEREWITH - A method and system for reduction or mitigation of metal contamination of polycrystalline silicon are disclosed. Metal contamination of granulate polycrystalline silicon, from contact with a metal surface of components of the supporting transportation and auxiliary infrastructure of a fluidized bed reactor unit, is mitigated by use of a protective coating comprising a microcellular elastomeric polyurethane. | 2014-01-23 |
20140023579 | CHEMICAL CARBON DIOXIDE GAS GENERATOR - A chemical carbon dioxide gas generator comprising:
| 2014-01-23 |
20140023580 | METHOD FOR CARRYING OUT A HYDROTHERMAL CARBONIZATION REACTION AND REACTION TANK FOR IT - Known methods for hydrothermal carbonization are very time-intensive, as the carbonization reaction only proceeds gradually in the biomass used therefor. This is because of the different reaction conditions prevailing in different parts of the biomass. These also cause an inhomogeneous reaction product. The object of the invention is both to accelerate the method and to improve the result. This is achieved by swirling the biomass inside the available reaction space with the aid of blower nozzles, which blow in the steam at a high speed so that the biomass is swirled. This ensures that the carbonization reaction can proceed uniformly and promptly after the biomass is introduced. | 2014-01-23 |
20140023581 | RECYCLING CARBON FIBERS FROM EPOXY USING SOLVENT CRACKING - Methods of extracting recycling carbon fibers are provided. Method of extracting and recycling carbon fibers with furan-2-carbaldehyde are provided and systems for performing the same are also provided. Compositions comprising resin composites, carbon fibers, and/or furan-2-carbaldehyde are also provided. | 2014-01-23 |
20140023582 | PHOTOSENSITIZERS AND USE THEREOF FOR GENERATING HYDROGEN FROM WATER - The invention relates to novel complexes and to the use thereof as photosensitizers for generating hydrogen from water. | 2014-01-23 |
20140023583 | METHOD OF MEASURING AND COMPARING LEVELS OF SUBSTANCES IN AN INDIVIDUAL'S BODY - A method for measuring the homeostatic relationship between various substances in the body. The measured levels of substances in the body use the interrelationships of the various substances in order to establish guidelines for treating individuals. | 2014-01-23 |
20140023584 | CONTRAST AGENT FOR PHOTOACOUSTIC IMAGING AND PHOTOACOUSTIC IMAGING METHOD USING THE SAME - It is intended to provide a novel contrast agent for photoacoustic imaging that is highly capable of binding to a target molecule and generates high photoacoustic signals. The present invention provides a contrast agent for photoacoustic imaging represented by Formula 1: | 2014-01-23 |
20140023585 | 177 LUTETIUM-LABELED BOMBESIN ANALOGS FOR RADIOTHERAPY - The invention is directed to novel Lutetium-177-labeled bombesin analogs for treatment of tumor by radiotherapy. | 2014-01-23 |
20140023586 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 2014-01-23 |
20140023587 | PHOSPHOLIPID ANALOGS AS DIAPEUTIC AGENTS AND METHODS THEREOF - The present invention provides methods and uses of phospholipid ether analogs as diagnostic and therapeutic agents for numerous cancers. | 2014-01-23 |
20140023588 | METHOD OF DRUG DELIVERY BY CARBON NANOTUBE CHITOSAN NANOCOMPLEXES - Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells. | 2014-01-23 |
20140023589 | FRMD4A ANTAGONISTS AND THEIR USES - An antagonist of FERM domain-containing protein 4A (FRMD4A) and/or of the Hippo pathway for use in a method of treating a cancer in a mammalian subject, wherein the cancer is selected from: squamous cell carcinoma (SCC), an epithelial cancer, an adenocarcinoma and a carcinoma is disclosed, as well as related methods of treatment of cancer, methods of screening and generating such antagonists, including anti-FRMD4A antibodies. | 2014-01-23 |
20140023590 | NOVEL BLOCK COPOLYMER AND MICELLE COMPOSITIONS AND METHODS OF USE THEREOF - Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R′ is —H or —CH | 2014-01-23 |
20140023591 | HETEROMULTIVALENT NANOPARTICLE COMPOSITIONS - A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle, the targeting moieties includes a first activated platelet targeting moiety and a second activated platelet targeting moiety. | 2014-01-23 |
20140023592 | SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS - A compound comprising three components A, B, and C, which components are covalently bound forming the compound having the structure A-B-C wherein
| 2014-01-23 |
20140023593 | IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS - A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. | 2014-01-23 |
20140023594 | MRI CONTRAST AGENT FOR LYMPHOGRAPHY BASED ON IRON OXIDE NANOPARTICLES AND METHOD FOR IMAGING LYMPH NODE USING THE SAME - Provided are a contrast agent for contrast imaging lymph node, which includes iron oxide nanoparticles dispersed and stabilized in an aqueous medium by a mussel adhesive protein-mimetic copolymer, a method for contrast enhanced lymphography using the foregoing contrast agent, and a method for diagnosis of lymph node cancers using the foregoing contrast agent. Using such a mussel adhesive protein-mimetic copolymer, the surface of iron oxide is modified and dispersed well in water to prepare a colloidal solution, which in turn forms the contrast agent containing the colloidal solution. The inventive contrast agent does not have toxicity and is easily taken up to the lymph node to exhibit excellent contrast imaging effects. The contrast agent of the present invention is useful for diagnosis of metastatic cancers. | 2014-01-23 |
20140023595 | INHALATION DEVICES AND RELATED METHODS FOR ADMINISTRATION OF SEDATIVE HYPNOTIC COMPOUNDS - An inhalation device for administering one or more sedatives via pulmonary inhalation for treating a sleep disturbance. | 2014-01-23 |
20140023596 | Novel Composition - An oral care composition which is a liquid at or below room temperature and which forms a two-phase cloudy system at body temperature and wherein the composition comprises a water-soluble non-ionic polymer, such as HPC, having a cloud point in the composition at a temperature no higher than about 38° C., for combating (i.e. helping to prevent, inhibit and/or treat) dentinal hypersensitivity. | 2014-01-23 |
20140023597 | ANTIMICROBIAL AND IMMUNOSTIMULATORY SYSTEM COMPRISING AN OXIDOREDUCTASE ENZYME - The present invention relates to an antimicrobial and immunostimulatory system, applications thereof and a process for the production of the antimicrobial and immunostimulatory system. The present invention provides a storage-stable antimicrobial and immunostimulatory system comprising an oxidoreductase enzyme, a substrate for the oxidoreductase enzyme and hydrogen peroxide in an aqueous solution wherein the substrate for the oxidoreductase enzyme is present up to 90% by weight and water is present up to 20% by weight based on the weight of the total composition; the system has a pH from approximately 4 to 8; and the system provides a two-stage hydrogen peroxide release. | 2014-01-23 |
20140023598 | FUNCTIONAL FRAGRANCE PRECURSOR - The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being of the formula X—O—C(R)(R*)(OR**) wherein R is a C | 2014-01-23 |
20140023599 | WATER-SOLUBLE PHARMACEUTICAL COMPOSITIONS OF HOPS RESINS - The present invention is drawn to water-soluble compositions for providing hops constituents, particularly alpha acids, iso-alpha acids, and beta acids. A pharmaceutical gel composition can comprise a hops extract and a surfactant. Such compositions can be formulated into products for various therapeutic applications, including oral and topical uses. Such compositions can also be dissolved in water to yield a clear solution containing more dilute hops acids. The invention also provides methods of treatment comprising administering water-soluble hops compositions. The present invention is also drawn to methods for making water-soluble preparations of hops constituents. | 2014-01-23 |
20140023600 | SKIN CARE COMPOSITION - The present invention relates to a composition for enhancing the overall quality of the skin and for treating aging skin, comprising from 0.05 to 5.0% by weight of a depolymerized hydroxypropyl guar having MS between 1.5 and 3.5, in a cosmetic or pharmaceutical acceptable carrier. | 2014-01-23 |
20140023601 | PERFORMANCE BOOSTING UV-ABSORBING COMPOUNDS - UV-absorbing compounds are disclosed that are derived from at least: (a) a UV absorber having at least one hydroxyl group, primary amine group, or secondary amine group, (b) a coupling agent having anhydride functionality, and (c) a graft host comprising an unsaturated fatty acid. These compounds absorb, scatter, deflect, or scatter ultraviolet radiation in a variety of personal care and performance chemical applications. | 2014-01-23 |
20140023602 | EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE - Provided is an external preparation for skin, comprising a phosphorylated saccharide. The phosphorylated saccharide may be an inorganic salt of a phosphorylated saccharide. The phosphorylated saccharide may be a calcium, magnesium, potassium, zinc, iron or sodium salt. Also provided is an external preparation for skin, comprising a phosphorylated saccharide and a second component, wherein the second component is selected from the group consisting of moisturizing agents, whitening components, ultraviolet absorbents, anti-inflammatory agents, cell-activating agents and antioxidants. The moisturizing agent may be ascorbic acid or an ascorbic acid derivative. | 2014-01-23 |
20140023603 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR - Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease. | 2014-01-23 |
20140023604 | EXTERNAL SKIN PREPARATION AND PRODUCTION METHOD OF SAME - Provided are: an external skin preparation that contains a whitening agent in the form of a resorcinol derivative and causes minimal irritation of the skin, and a production method thereof. The external skin preparation contains 0.1% by weight to 5% by weight of the resorcinol derivative and 0.01% by weight to 5% by weight of the ascorbyl 2-phosphate-6-palmitate. | 2014-01-23 |
20140023605 | PROCESS FOR PRODUCING A CONDITIONING CLEANING AGENT - A process for producing a conditioning cleaning agent includes the steps of: a) providing a microemulsion, containing (i) at least one alkyl(oligo)glycoside, (ii) at least one ester of glycerin with at least one C | 2014-01-23 |
20140023606 | PROCESS FOR PRODUCING A CONDITIONING CLEANING AGENT - A process for producing a conditioning cleaning agent includes a) providing a microemulsion including (i) at least one alkyl(oligo)glycoside, (ii) at least one ester of glycerin with at least one C | 2014-01-23 |
20140023607 | NOVEL ETHYLENIC COPOLYMERS, COMPOSITIONS AND METHODS OF THE SAME - The present disclosure relates to novel ethylenic copolymers comprising from 10% to 80% by weight, of at least one monomer of polyethylene glycol (meth)acrylate type, from 20% to 90% by weight, of at least one anionic monomer, and from 0% to 70% by weight, at least one additional nonionic hydrophilic monomer. The disclosure also relates to a composition, such as cosmetic or pharmaceutical compositions, comprising the copolymers and to a method of using the same. | 2014-01-23 |
20140023608 | NOVEL ETHYLENIC COPOLYMERS, COMPOSITIONS AND METHODS OF THE SAME - The present disclosure relates to novel ethylenic copolymers comprising from 10% to 80% by weight, of at least one monomer of polyethylene glycol (meth)acrylate type, from 20% to 90% by weight, of at least one anionic monomer, and from 0% to 70% by weight, at least one additional nonionic hydrophilic monomer. The disclosure also relates to a composition, such as cosmetic or pharmaceutical compositions, comprising the copolymers and to a method of using the same. | 2014-01-23 |
20140023609 | CLEANING COMPOSITIONS - The present invention relates to cleaning composition, preferably a laundry detergent composition, comprising a foam control composition comprising a hydrophobically modified cationic polymer, as well as processes for making and method of using such compositions. The composition of the present invention provides for enhanced suds removal during the rinse cycle with minimal or nil impact on suds volume during the wash cycle. | 2014-01-23 |
20140023610 | SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION - This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing. | 2014-01-23 |
20140023611 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. | 2014-01-23 |
20140023612 | Granulocyte-Macrophage Colony Stimulating Factor for Enhancing Pulmonary Host Defense in Acute and Chronic Radiation Syndrome, Therapeutic Radiation Intervention and Cancer Therapy - Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided. | 2014-01-23 |
20140023613 | Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Vaccine Comprising The Same - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequence of HBV core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against HBV using the nucleic acid sequences that are provided. | 2014-01-23 |
20140023614 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF - The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them. | 2014-01-23 |
20140023615 | THERMO-SENSITIVE, MUCOADHESIVE OR DERMOADHESIVE, AND PENETRATION-ENHANCING FORMULATIONS FOR TOPICAL DELIVERY OF THERAPEUTICS - The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment, the biopolymer formulation comprises co-polymer of poloxamer 188 and propylene glycol, laurocapram and, optionally, one or more therapeutic agents. Also provided are uses of the biopolymer formulations for topical therapy of cancer including cervical cancer. | 2014-01-23 |
20140023616 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2014-01-23 |
20140023617 | METHOD FOR TREATING IFNALPHA RELATED CONDITIONS - An immunogenic product including IFNα coupled to a carrier protein molecule is capable to induce in vivo anti-IFNα antibodies and is useful in treating IFNα related conditions. | 2014-01-23 |
20140023618 | SYSTEMS AND METHODS FOR TREATMENT OF ANDROGENETIC SKIN CONDITIONS BY MICROBIAL ORGANISMS - A specific naturally occurring or genetically modified bacterial strain can be introduced into the hair follicle of patients suffering from androgenetic alopecia as to reduce the bioavailable extracellular testosterone and hence reduce the effect of androgens on the hair follicle. | 2014-01-23 |
20140023619 | VIRAL VECTOR TARGETING CANCER STEM CELLS - [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer. | 2014-01-23 |
20140023620 | PROBIOTIC COMPOSITION - Disclosed herein are probiotic compositions comprising a mixture of at least two probiotic bacteria, including | 2014-01-23 |
20140023621 | BONE MARROW DERIVED CD271 PRECURSOR CELLS FOR CARDIAC REPAIR - Methods for the isolation of CD271 | 2014-01-23 |
20140023622 | Brown Fat Cell Compositions and Methods - Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. | 2014-01-23 |
20140023623 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby - A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs. | 2014-01-23 |
20140023624 | DECELLULARIZED LIVER TRANSPLANTATION COMPOSITION AND METHODS - This disclosure provides an isolated or purified decellularized liver extracellular matrix (DLM) composition containing an isolated or purified cell capable of differentiating into a hepatocyte and/or liver tissue, and methods for its use in vitro and in vivo. | 2014-01-23 |
20140023625 | BIOLOGICAL EFFECTS OF COMPOSITIONS OF ROSMARINIC ACID - The present invention relates to compositions of rosmarinic acid or its derivatives and to the use of a hydrolytic enzyme or of microorganism containing or producing hydrolytic enzymes in these compositions. The invention also pertains to methods for improving the biological effects of the rosemary extracts and for administering such compositions to a human or animal subject for improving the skin, coat, hair or health of the subject. | 2014-01-23 |
20140023626 | Enhancement of Natural Killer (NK) Cell Proliferation and Activity - Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with an aryl hydrocarbon antagonist in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof. | 2014-01-23 |
20140023627 | TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. | 2014-01-23 |
20140023628 | SITE-DIRECTED PEGYLATION OF ARGINASES AND THE USE THEREOF AS ANTI-CANCER AND ANTI-VIRAL AGENTS - The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys | 2014-01-23 |
20140023629 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): | 2014-01-23 |
20140023630 | Human Cystathionine Beta-Synthase Variants and Methods of Production Thereof - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described. | 2014-01-23 |
20140023631 | METHODS OF TREATING ANEMIA AND RED BLOOD CELL DYSFUNCTION WITH LECITHIN CHOLESTEROL ACYLTRANSFERASE - Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells. | 2014-01-23 |
20140023632 | PHARMACEUTICAL FORMULATION - A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant. | 2014-01-23 |
20140023633 | USE OF BETA-1,3 (4)-ENDOGLUCANOHYDROLASE, BETA-1,3 (4)-GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION - A method for the augmentation of immune function is described. The invention comprises a combination of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species. | 2014-01-23 |
20140023634 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2014-01-23 |
20140023635 | SINGLE NUCLEOTIDE POLYMORPHISMS AND GENES ASSOCIATED WITH T2D-RELATED COMPLICATIONS - The invention provides with means to predict, in subjects affected by type-2-diabetes (T2D), the probability of developing complications related to the disease. The invention involves (1) identification of genetic features such as single nucleotide polymorphisms (SNPs) for the establishment of a patient profile that can be used for prediction of complications associated with T2D. Signature profiles comprising a combination of SNPs which have greater predictive value for prognosticating particular types of complications, such as, stroke, myocardial infarction and kidney complications associated with T2D are further described. Compositions and kits that can be used with a set of complementary phenotypic markers to evaluate the risk for an individual affected by T2D to develop complications related to the disease and to evaluate the likelihood that an individual affected by type 2 diabetes type will benefit from treatments that collectively aim to reduce the risk of developing such complications. | 2014-01-23 |
20140023636 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF - The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. | 2014-01-23 |
20140023637 | Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. | 2014-01-23 |
20140023638 | ANTIBODY TO GDF8 AND USES THEREOF - The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2014-01-23 |
20140023639 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2014-01-23 |
20140023640 | METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2014-01-23 |
20140023641 | ANTIBODY WITH SPECIFICITY FOR GM-CSF (I) - The present invention relates to antibodies with specificity for granulocyte-macrophage colony stimulating factor (GM-CSF). More particularly, the invention relates to humanized monoclonal antibodies that bind specifically to human GM-CSF with high affinity. The invention also relates to nucleic acids encoding the antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis or treatment of autoimmune or inflammatory diseases. | 2014-01-23 |
20140023642 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof - Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R | 2014-01-23 |
20140023643 | N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES - This invention provides compounds of Formula I | 2014-01-23 |
20140023644 | Antibodies Specific for TGF-Beta - The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. | 2014-01-23 |
20140023645 | ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES - Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen. | 2014-01-23 |
20140023646 | Compositions and Methods for Treating Viral Infection - Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus. | 2014-01-23 |
20140023647 | METHOD FOR TREATING SOLID TUMORS - Provided herein are methods for treating a solid tumor in a subject in need thereof by activating an immune response against a tumor antigen. Also provided are methods for treating a solid tumor in a subject in need thereof by activating antigen-presenting cells and eliciting an immune response against a tumor antigen. Also provided herein are optimized therapeutic treatments of solid tumors, which comprise determining the presence, absence or amount of a biomarker after the therapy has been administered, and determining whether a subsequent dose of the therapy should be maintained, increased, or decreased based on the biomarker assessment. | 2014-01-23 |
20140023648 | Treatment of Osteoarthritis Using IL-20 Antagonists - Methods for alleviating or delaying the onset of osteoarthritis in a subject in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20, e.g., an anti-IL-20 antibody. | 2014-01-23 |